The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) recently announced that its second annual ACTRIMS Forum will be at the Omni ChampionsGate Feb. 23-25, 2017, in Orlando, Florida.
ACTRIMS Forum 2017 promises to be of value to physicians, scientists, researchers, analysts, faculty, and allied health professionals, examining the advances in research and treatment of multiple sclerosis (MS) in the care of patients.
The focus of next year’s forum will be environmental factors, genetics, and epigenetics in MS susceptibility and clinical course. Presenters will disclose recent advances on the relationship between MS susceptibility and diet; the effects of sex chromosomes, hormones, and puberty on the risk of MS and the clinical course of the disease; reveal emerging data on the role of the microbiome in MS development; review controversies regarding the role of viruses in MS; convey state-of-the-art data on genetic and epigenetic factors as risk factors and disease modulators in MS; and other MS-related topics of interest.
The ACTRIMS Forum 2017 will also provide exclusive networking opportunities with some of the leading scientists in the field.
A limited number of ACTRIMS Forum 2017 Educational Grants will be awarded to young investigators including students, residents, postdoctoral fellows and junior faculty whose abstracts are accepted for a platform or poster presentation.
Four endMS Research and Training Travel Awards will be granted by the MS Society of Canada for those with an active endMS Postdoctoral Fellowship or Doctoral Studentship Award who have had an accepted abstract for the ACTRIMS Forum.
Four National MS Society Travel Awards will be granted to society-funded trainees among those whose abstracts are accepted for the ACTRIMS Forum.
ACTRIMS is an event that meets three times a year with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). More than 600 researchers and clinicians attended ACTRIMS Forum 2016, held in New Orleans.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?